These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26033033)

  • 1. C-Cell Neoplasia in Asymptomatic Carriers of RET Mutation in Extracellular Cysteine-Rich and Intracellular Tyrosine Kinase Domain.
    Abi-Raad R; Virk RK; Dinauer CA; Prasad A; Morotti RA; Breuer CK; Sosa JA; Udelsman R; Rivkees SA; Prasad ML
    Hum Pathol; 2015 Aug; 46(8):1121-8. PubMed ID: 26033033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
    Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L
    Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
    Moore SW; Appfelstaedt J; Zaahl MG
    J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
    Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
    Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
    Fitze G; Saeger HD; Roesner D; Schackert HK
    Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic testing in multiple endocrine neoplasia and related syndromes.
    Calender A
    Forum (Genova); 1998; 8(2):146-59. PubMed ID: 9666051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature].
    de Groot JW; Links TP; Rouwe CW; van der Wal JE; Hofstra RM; Plukker JT
    Ned Tijdschr Geneeskd; 2006 Feb; 150(6):311-8. PubMed ID: 16503023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
    J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical diagnosis and treatment of familial medullary thyroid carcinoma caused by a p.C618Y RET proto-oncogene mutation in a Chinese pedigree].
    Zhao JQ; Guo L; Qi XP; Chen ZG; Wang KJ; Lou JL; Yu XH; Cheng J; Jin HY; Li XL; Ying RB; Zhang XN
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(6):440-4. PubMed ID: 23660264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early malignant progression of hereditary medullary thyroid cancer.
    Machens A; Niccoli-Sire P; Hoegel J; Frank-Raue K; van Vroonhoven TJ; Roeher HD; Wahl RA; Lamesch P; Raue F; Conte-Devolx B; Dralle H;
    N Engl J Med; 2003 Oct; 349(16):1517-25. PubMed ID: 14561794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
    Kameyama K; Okinaga H; Takami H
    Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
    Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
    Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetrance and clinical manifestations of non-hotspot germline RET mutation, C630R, in a family with medullary thyroid carcinoma.
    Dourisboure RJ; Belli S; Domenichini E; Podestá EJ; Eng C; Solano AR
    Thyroid; 2005 Jul; 15(7):668-71. PubMed ID: 16053382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
    Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
    Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype.
    Frank-Raue K; Buhr H; Dralle H; Klar E; Senninger N; Weber T; Rondot S; Höppner W; Raue F
    Eur J Endocrinol; 2006 Aug; 155(2):229-36. PubMed ID: 16868135
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.